ENTITY
Shanghai Bio-heart Biological Technology

Shanghai Bio-heart Biological Technology (2185 HK)

20
Analysis
Industrials • China
Shanghai Bio-heart Biological Technology is an interventional cardiovascular device company that develops innovative therapies for unmet medical needs in the treatment of coronary artery disease and hypertension. Its key products include the Bioheart bioresorbable scaffolds (BRS) system, the Iberis 2nd renal denervation (RDN) product candidate, and drug-coated balloons (DCB). The company was founded in 2014 and is headquartered in Shanghai, People's Republic of China.
more
•23 Jun 2021 14:18

Shanghai Bio-Heart (äøŠęµ·ē™¾åæƒå®‰) Pre-IPO: Thoughts on Valuation

We provide a pre-money based valuation for Shanghai Bio-heart listing. We forecast the sales for its BRS and RDN respectively. We would re-iterate...

Logo
444 Views
Share
•07 Apr 2021 08:38

Pre-IPO Shanghai Bio-Heart Biological Technology - Here Are the Strength and Concerns

The article analyzed Shanghai Bio-Heart Biological in terms of strength (core product, market potential) and concerns (competition, intensive...

Logo
530 Views
Share
bullish•Zhihu Technology
•28 Mar 2021 09:05

ECM Weekly (28th March 2021) - Bairong, Bilibili HK, Linklogis, Energy Monster, Zhihu, Monde Nissin

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Share
•24 Mar 2021 16:28

Shanghai Bio-Heart (äøŠęµ·ē™¾åæƒå®‰) Pre-IPO: Needs a Long Runway

The company's management were mainly from Microport Scientific. It has decent investor backing but we think it is short of blockbuster products.

Logo
804 Views
Share
x